For Patients

?

Pancreatic Cancer Trials

Rainier

Phase 2 Clinical Trial in Metastatic Pancreatic Cancer

Rainier™ is an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen in combination with Abraxane® (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Rainier is designed to evaluate the potential benefit of adding apatorsen to Abraxane and gemcitabine therapy by measuring the treatments’ impact on survival. The trial is sponsored by the Sarah Cannon Research Institute (SCRI).

To see if you qualify, visit mytrialmatch.com or call 1-855-216-0159
Learn more about the Rainier Trial

 

External Link Pop Up Window

You are now exiting the OncoGenex Web site and entering a third party Web site.

OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.

Stay on OncoGenex Continue